Summit Therapeutics (SMMT) Cash & Current Investments: 2016-2025
Historic Cash & Current Investments for Summit Therapeutics (SMMT) over the last 9 years, with Sep 2025 value amounting to $238.9 million.
- Summit Therapeutics' Cash & Current Investments rose 153.86% to $238.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year increase of 253.58%. This contributed to the annual value of $412.3 million for FY2024, which is 121.40% up from last year.
- Latest data reveals that Summit Therapeutics reported Cash & Current Investments of $238.9 million as of Q3 2025, which was down 19.89% from $298.2 million recorded in Q2 2025.
- In the past 5 years, Summit Therapeutics' Cash & Current Investments ranged from a high of $648.6 million in Q4 2022 and a low of $28.8 million during Q2 2024.
- In the last 3 years, Summit Therapeutics' Cash & Current Investments had a median value of $215.0 million in 2023 and averaged $212.5 million.
- In the last 5 years, Summit Therapeutics' Cash & Current Investments slumped by 86.63% in 2024 and then skyrocketed by 937.04% in 2025.
- Summit Therapeutics' Cash & Current Investments (Quarterly) stood at $71.8 million in 2021, then surged by 803.47% to $648.6 million in 2022, then plummeted by 71.29% to $186.2 million in 2023, then soared by 121.40% to $412.3 million in 2024, then surged by 153.86% to $238.9 million in 2025.
- Its Cash & Current Investments was $238.9 million in Q3 2025, compared to $298.2 million in Q2 2025 and $361.3 million in Q1 2025.